Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024

Nirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hospitalized during the 2023-2024 season, nirsevimab was 86.0% and 87.9% effective among children entering their first and second RSV seasons, respectively.

Authors

Institutions

Publication Details

Journal
The Pediatric Infectious Disease Journal
Published
2025-10-17
DOI
https://doi.org/10.1097/inf.0000000000004942
Citations
1
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
1.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024

Mila M. Prill, Fernando Cardona, Fatimah S. Dawood, Judith Espinoza et al.
1 citations
The Pediatric Infectious Disease Journal
Respiratory viral infections research
1.35
article

Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023–2024

Mila M. Prill, Fernando Cardona, Fatimah S. Dawood, Judith Espinoza, Rosalyn Singleton, Rachel M. Hartman, Natasha Halasa, Nina Ritchie, Christine Desnoyers, Kelly Menachof, Meredith McMorrow, Chloe Hurley, Catherine G. Sutcliffe, Amanda Burrage, James McAuley, James W. Keck, Rasmus Larsen, James D. Chappell, Angela P. Campbell, Jennifer Dobson, Marqia Sandoval, L. Oxley, Loretta Christensen, Laura L. Hammitt, Dennie Parker Riley, Gilberto Alvarez-Colon
article en
1 citations

Abstract

Nirsevimab is recommended to prevent severe respiratory syncytial virus (RSV)-associated illness among American Indian/Alaska Native (AI/AN) children <20 months of age. In a test-negative case-control analysis among 291 AI/AN children hospitalized during the 2023-2024 season, nirsevimab was 86.0% and 87.9% effective among children entering their first and second RSV seasons, respectively.

The Pediatric Infectious Disease JournalVol. 44(12)
Centers for Disease Control and Prevention (US), Alaska Native Tribal Health Consortium (US), Johns Hopkins University (US), Indian Health Service (US), Yukon Kuskokwim Health Corporation (US), Tsehootsooi Medical Center (US), Gallup Indian Medical Center (US), Tuba City Regional Health Care (US), Vanderbilt University Medical Center (US)
Openalex Percentile: Top 15%
Respiratory viral infections research
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.